

Kayentis offers extensive expertise in dermatology and a solid experience with several typical PROs, ClinROs and Patient Diaries.

With a large set of data collection modes, an efficient instant score calculation, key patient engagement features, and high quality data management performed throughout the process, Kayentis contributes to the success and quality of dermatology clinical trials.

Learn more how with our case study!

- 50+ studies, 12,000+ patients, 2,500 sites
 - 60+ countries/languages per study
- Adult, elderly, teenage, and pediatric populations
 - 85% Phase II/III

DERMATOLOGY CASE STUDY

Kayentis

offers extensive experience in **dermatology**


- **50+** studies, 12,000+ patients, 2,500 sites
- **60+** countries/languages per study
- **Adult, elderly, teenage, and pediatric** populations
- **85%** Phase II/III

Indications:

- ✓ Atopic Dermatitis, Prurigo Nodularis
- ✓ Chronic Urticaria, Chronic Spontaneous Urticaria, Eczema
- ✓ Psoriasis, Nail Psoriasis, Palmoplantar Psoriasis
- ✓ Hidradenitis suppurativa and hyperhidrosis

ePRO, eClinRO, eObsRO, and eDiary assessments:

- Typically, site-based PROs and ClinROs combined with home eDiary
- **Complete ClinRO** build with fast data entry and efficient score calculation: PASI, EASI, IGA, BSA, SCORAD
- **Solid experience with several typical PROs:** DLQI, WPAI, and NAPPa with different components (NAPPa-QoL, NAPPa-PBI, UCT & AECT, PFQ)
- **Extensive experience with Patient Diaries:** VRS, NRS Skin Pain-Itch Scale, Patient's Lesion Count, Worst Pain – NRS, such as Pruritus NRS, Pruritus PCS, Sleep Disturbance NRS, DPS, UPDD, Medication Log, Rescue Medication, CholUAS?, UPSS with UAS and AAS



Download our dermatology case study
Contact us for more information

Key Words:

- eCOA
- ePRO
- eDiary
- dermatology
- clinical trial

[Learn more:](#)



Rethinking pediatric clinical trials: guidelines from pediatric experts

2 April 2024

In this last episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



Overcoming challenges in long-lasting pediatric clinical trials – Insights from site experts

26 March 2024

In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



Tackling the specificities of NASH/MASH clinical trials

26 March 2024

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating

[Read More »](#)



Mastering pediatric asthma clinical trials

19 March 2024

Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of

[Read More »](#)



The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

14 March 2024

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally

[Read More »](#)



How DCTs Can Help Pediatric Clinical Research – Insights From Site

Experts

12 March 2024

In this second episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)